Comparative effectiveness of metronidazole and vancomycin for treatment of Clostridioides difficile infection in hospitalized children

被引:0
|
作者
Sandora, Thomas J. [1 ,2 ]
Savage, Timothy J. [1 ,2 ,3 ]
Ryan, Morgan E. [4 ]
Dahlberg, Suzanne E. [2 ,4 ,5 ]
Daugherty, Kaitlyn [2 ,6 ]
Kelly, Ciaran P. [2 ,6 ]
Pollock, Nira R. [2 ,7 ,8 ]
Kociolek, Larry K. [9 ,10 ]
机构
[1] Boston Childrens Hosp, Dept Pediat, Div Infect Dis, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA
[4] Boston Childrens Hosp, Biostat Res & Design Ctr, Boston, MA USA
[5] Boston Childrens Hosp, Dept Pediat, Div Pulm Med, Boston, MA USA
[6] Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA USA
[7] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA USA
[8] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA
[9] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Div Infect Dis, Chicago, IL USA
[10] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
基金
美国国家卫生研究院;
关键词
HEALTH-CARE EPIDEMIOLOGY; DISEASES SOCIETY; AMERICA IDSA; GUIDELINES; MANAGEMENT; UPDATE;
D O I
10.1017/ash.2025.51
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To compare rates of clinical response in children with Clostridioides difficile infection (CDI) treated with metronidazole vs vancomycin.Design: Retrospective cohort study was performed as a secondary analysis of a previously established prospective cohort of hospitalized children with CDI. For 187 participants 2-17 years of age who were treated with metronidazole and/or vancomycin, the primary outcome of clinical response (defined as resolution of diarrhea within 5 days of treatment initiation) was identified retrospectively. Baseline variables associated with the primary outcome were included in a logistic regression propensity score model estimating the likelihood of receiving metronidazole vs vancomycin. Logistic regression using inverse probability of treatment weighting (IPTW) was used to estimate the effect of treatment on clinical response.Results: One hundred seven subjects received metronidazole and 80 subjects received vancomycin as primary treatment. There was no univariable association between treatment group and clinical response; 78.30% (N = 83) of the metronidazole treatment group and 78.75% (N = 63) of the vancomycin group achieved clinical response (P = 0.941). After adjustment using propensity scores with IPTW, the odds of a clinical response for participants who received metronidazole was 0.554 (95% CI: 0.272, 1.131) times the odds of those who received vancomycin (P = 0.105).Conclusions: In this observational cohort study of pediatric inpatients with CDI, the rate of resolution of diarrhea after 5 days of treatment did not differ among children who received metronidazole vs vancomycin.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] COMPARATIVE EFFICACY OF FIDAXOMICIN, VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION: A NETWORK META-ANALYSIS
    Okumura, H.
    Fukushima, A.
    Taieb, V
    Shoji, S.
    English, M.
    VALUE IN HEALTH, 2018, 21 : S222 - S222
  • [22] REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION
    Dubberke, Erik R.
    Puckett, Justin T.
    Obi, Engels N.
    Kamal-Bahl, Sachin
    Desai, Kaushal
    Stuart, Bruce
    Doshi, Jalpa A.
    GASTROENTEROLOGY, 2022, 162 (07) : S157 - S157
  • [23] Oral fidaxomicin versus vancomycin for Clostridioides difficile infection
    Long, Brit
    Gottlieb, Michael
    ACADEMIC EMERGENCY MEDICINE, 2022, 29 (12) : 1506 - 1507
  • [24] Vancomycin in the treatment of inflammatory bowel disease: there is a role beyond Clostridioides difficile infection
    Calderon, Paula
    Damas, Oriana M.
    Nunez, Paulina
    Quera, Rodrigo
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (09) : 500 - 501
  • [25] Treatment of Clostridioides difficile Infection
    Sehgal, Kanika
    Cifu, Adam S.
    Khanna, Sahil
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (09): : 881 - 882
  • [26] Oral Vancomycin as Secondary Prophylaxis for Clostridioides difficile Infection
    Bao, Hongkai
    Lighter, Jennifer
    Dubrovskaya, Yanina
    Merchan, Cristian
    Siegfried, Justin
    Papadopoulos, John
    Jen, Shin-Pung
    PEDIATRICS, 2021, 148 (02)
  • [27] Treatment of Clostridioides difficile Infection
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1632): : 137 - 141
  • [28] Diversity of Circulating Clostridioides difficile Ribotypes in Mexico and Susceptibility to Fidaxomicin, Vancomycin, and Metronidazole
    Martinez-Melendez, Adrian
    Tijerina-Rodriguez, Laura
    Collins, Nathania
    Baines, Simon D.
    Morfin-Otero, Rayo
    Camacho-Ortiz, Adrian
    Villarreal-Trevino, Licet
    Garza-Gonzalez, Elvira
    MICROBIAL DRUG RESISTANCE, 2021, 27 (12) : 1672 - 1676
  • [29] Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection- An observational cohort study
    Hernando-Gozalo, Marcos
    Rescalvo-Casas, Carlos
    Seijas-Pereda, Laura
    Cuadros-Gonzalez, Juan
    Perez-Tanoira, Ramon
    HELIYON, 2024, 10 (10)
  • [30] Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children
    Cross, Shane J.
    Morton, Theodore H.
    Wolf, Joshua
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 : S46 - S51